Statistical Considerations in Early Phase Clinical Trial Design in the Era of Targeted Therapy and Immunotherapy
Mark Krailo, PhD
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok
